A GLP-1RA drug-loaded nanoparticle and preparation and preparation method thereof
Through inorganic nanomaterial carrier-mediated and permeable promotion technology, the degradation and absorption of polypeptide drugs in the gastric tract is solved, and the high bioavailability and rapid absorption of GLP-1RA is achieved, the preparation process is simplified, and the drug dissolution rate is improved. and recovery rate.
Patent Information
- Application Number
- CN202410814362.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-24
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-06-24
AI Technical Summary
Polypeptide drugs are easily degraded by digestive enzymes in the gastric tract and are difficult to absorb through the intestinal wall, resulting in limited oral administration methods, affecting the bioavailability of the drug and patient compliance.
Using inorganic nanomaterial carrier-mediated technology and penetration promotion technology, gastroally adhered inorganic nanoparticles are used as carriers, combining specific surface modifiers and penetration promoters to protect GLP-1RA from gastrointestinal degradation and provide a variety of absorptions pathway to improve its stomach wall absorption capacity and solubility.
It significantly improves the bioavailability of GLP-1RA, achieves efficient oral absorption, enhances the dissolution rate and recovery rate of the drug, simplifies the preparation process, and reduces the complexity and instability of the preparation.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and relates to a GLP-1RA drug-loaded nanoparticle and a preparation and a preparation method thereof, and specifically relates to a GLP-1RA drug-loaded nanoparticle and a preparation for enhancing oral bioavailability and a preparation method thereof. Background Art
[0002] Glucagon-like peptide-1 receptor agonists (GLP-1RA) are a class of polypeptide drugs that simulate glucagon-like peptide-1 (GLP-1) in the human body. GLP-1RA can stimulate insulin secretion, inhibit gastric emptying, and increase satiety, thereby lowering blood sugar and body weight. It is mainly used to treat type 2 diabetes and obesity, and has good blood sugar-lowering efficacy and cardiovascular safety. In addition, GLP-1RA not only has a blood sugar-lowering effect, but also has the function of protecting the cardiovascular, kidney, nerve and other organs.
[0003] A major problem with peptide drugs is that their oral administration is subject to various restrictions, such as: peptide drugs are easily degraded by digestive enzymes in the gastric tract and are difficult to absorb through the intestinal wall. Therefore, peptide drugs usually need to be administered by injection, which not only brings inconvenience and pain to patients, but also affects drug compliance. In order to solve the above problems, researchers are committed to developing oral peptide preparation technology to protect peptide drugs from degradation in the gastrointestinal tract and increase the intestinal absorption of peptide drugs, thereby achieving oral administration.
[0004] Among them, the invention patent with publication number MX2017004592A discloses a peptide or protein drug with a specific molecular weight combined with a copper salt / complex and / or a zinc salt / complex and a reducing agent for oral administration for the treatment and prevention of diseases or conditions; the drug includes a component absorption promoter, and the absorption promoter includes 8-20 carbon alkanoyl carnitine, salicylic acid, salicylic acid derivatives, 3-methoxysalicylic acid, 5-methoxysalicylic acid, homovanillic acid, 8-20 carbon alkanoic acid, citric acid, fatty acid acylated amino acids, 8-20 carbon alkanoyl sarcosinates, alkyl sugars, 8-10 carbon alkyl polysaccharides, N-octyl-β-D-pyranoglucoside, N-dodecyl β-D-maltoside, cyclodextrin, α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, methyl-β-cyclodextrin, hydroxypropyl β-cyclodextrin, sulfonyl β-cyclodextrin, sodium N-[8-(2-hydroxybenzoyl)amino]octanoate, sulfopolymer, calcium chelate, ethylenediaminetetraacetic acid, ethylene glycol tetraacetic acid, benzalkonium chloride, betastatin, cetylpyridinium chloride, cetyltrimethylammonium bromide, 2-20 carbon chain alkanol, 8-20 carbon chain alkenol, 8-20 carbon chain alkenoic acid, dextran sulfate, diethylene glycol monoethyl ether, 1-dodecylazacycloheptane-2 -ketone, ethyl caprylate, monolaurin, lysophosphatidylcholine, menthol, 8-20 carbon alkylamine, 8-20 carbon alkenylamine, phosphatidylcholine, poloxamer, polyethylene glycol monolaurate, polyoxyethylene, polypropylene glycol monolaurate, polysorbate, deoxycholate, sodium glycocholate, sodium glycodeoxycholate, sodium lauryl sulfate, taurocholate, taurodeoxycholate, or salts thereof.
[0005] In addition, the invention patent with publication number EP3359181A1 discloses an improved pharmaceutical preparation, and the orally administered peptide drug has high bioavailability and safety. The pharmaceutical composition provided by the invention comprises: a peptide drug having a molecular weight equal to or less than 5 kDa; a pharmaceutically acceptable copper salt complex and / or a pharmaceutically acceptable zinc salt / complex thereof and / or a pharmaceutically acceptable iron salt / complex thereof; and a pharmaceutically acceptable chelating agent. The pharmaceutical composition also contains an absorption promoter, which is selected from 8-20 carbon alkanoyl carnitines, salicylic acid, compounds of salicylic acid derivatives, 3-methoxysalicylic acid, 5-methoxysalicylic acid, homovanillic acid, 8-20 carbon chain alkanoic acid, citric acid, tartaric acid and fatty acid acylated amino acids, and / or their salts.
[0006] At present, a variety of preparation methods for oral peptide preparations have been proposed, mainly including the following categories:
[0007] Chemical modification method: By changing the chemical structure of peptide drugs, their stability and lipophilicity are increased, thereby improving their resistance to degradation and absorption. This technology can effectively improve the bioavailability of peptide drugs; however, it also has some disadvantages, such as the possibility of affecting the biological activity of peptide drugs, increasing the cost and complexity of synthesis, and requiring additional safety evaluation.
[0008] Carrier-mediated method: By encapsulating peptide drugs in various carriers, they are protected from degradation in the gastrointestinal tract, and the special properties of the carriers are utilized to promote their absorption through the intestinal wall. This technology can effectively protect peptide drugs and provide multiple absorption pathways, such as transcellular, paracellular, M-cell, etc.; however, it may affect the release and distribution of peptide drugs, increase the complexity and instability of the preparation, and the biocompatibility and toxicity of the carrier must also be considered during use.
[0009] Permeation enhancer method: by adding some substances that can change the intestinal barrier, the intestinal permeability of the peptide drug is increased, thereby improving its absorption capacity. This technology can effectively increase the absorption of peptide drugs; however, it also has some disadvantages, such as the possibility of causing damage and irritation to the intestinal wall and affecting the normal function of the intestine. The dosage and safety of the permeation enhancer must also be considered when applying it.
[0010] In view of the above technical problems, the present invention combines inorganic nanomaterial carrier-mediated technology and penetration-enhancing technology to prepare GLP-1RA preparations, thereby preparing safe, stable and highly oral bioavailable glucagon-like peptide-1 pharmaceutical preparations. Summary of the invention
[0011] The present invention aims at the problems existing in the prior art, provides a GLP-1RA drug-loaded nanoparticle and preparation and a preparation method thereof, combines the use of inorganic nanomaterial carrier-mediated technology and permeation-enhancing technology, uses gastric-adherent inorganic nanoparticles as GLP-1RA carriers, effectively protects oral polypeptide drugs from degradation in the gastrointestinal tract, and provides multiple absorption pathways to improve its gastric wall absorption capacity; uses a specific surface modifier to increase the drug loading and drug recovery rate of the nanoparticles, increases the lipophilicity of the nanoparticles, and promotes its permeation through the gastric wall; uses an osmotic pressure enhancer, uses a specific type of permeation enhancer to change the physical and biochemical properties of the gastric wall barrier, increases the gastric wall permeability of the oral polypeptide drug, thereby improving its absorption capacity, and increasing the solubility and bioavailability of the drug. The GLP-1RA preparation drug prepared by the present invention has a high dissolution rate of the main drug and the permeation enhancer, and the bioavailability is significantly improved.
[0012] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0013] First, the present invention provides a method for preparing GLP-1RA drug-loaded nanoparticles, comprising the steps of:
[0014] (1) Dissolving and mixing GLP-1RA, surface modifier 1 and metal salt to obtain liquid A;
[0015] (2) dissolving and mixing the surface modifier 2 and the medicinal component containing acid radicals or hydroxide ions to obtain liquid B;
[0016] (3) Mixing solution A and solution B, adjusting the pH, forming a precipitate, and obtaining GLP-1RA drug-loaded nanoparticles;
[0017] The surface modifier 1 is selected from at least one of Tween, Span, Poloxamer, sodium dodecyl sulfate, polyoxyethylene castor oil, bile acid and its salts, polyethylene glycol (PEG) and its derivatives, phospholipids, block copolymer Pluronic series, block copolymer P123, amphiphilic polypeptide, polyethylene oxide (PEO), polypropylene oxide (PPO), chitosan, hyaluronic acid, gum arabic, albumin, gelatin, polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), polycaprolactone (PCL), sodium alginate, dextran, and dextran;
[0018] The surface modifier 2 is selected from bile acid and its derivatives, cholesterol and its derivatives, phosphatidylcholine (PC), phosphatidylethanolamine (PE), poloxamer F68, poloxamer F127, chitosan and its derivatives, polyglutamic acid (PGA), polylysine (PLL), polylactic acid (PLA), and polycaprolactone (PCL).
[0019] Preferably, the dissolution and mixing process occurs in a buffered saline solution, which is a biocompatible buffered saline solution; the buffered saline solution is selected from at least one of phosphate buffered saline (PBS), Hank's balanced salt solution (including components: sodium chloride, potassium chloride, phosphate, sodium bicarbonate and glucose), Tris (tris(hydroxymethylaminomethane) hydrochloride) buffer, TAE buffer (including components: tris(hydroxymethylaminomethane), acetic acid and ethylenediaminetetraacetic acid), TBE buffer (including components: tris(hydroxymethylaminomethane), boric acid and ethylenediaminetetraacetic acid), MOPS (3-(N-morpholine)propanesulfonic acid) buffer, glycine buffer and HEPES (4-hydroxyethylpiperazineethanesulfonic acid) buffer.
[0020] Preferably, the amphipathic polypeptide is a peptide segment composed of multiple amino acids, including a polypeptide composed of amphipathic amino acids, or a polypeptide composed of hydrophilic amino acids and hydrophobic amino acids; the amphipathic amino acids are selected from at least one of asparagine (Asn) and glutamine (Gln); the hydrophilic amino acids are selected from at least one of aspartic acid (Asp), glutamic acid (Glu), lysine (Lys), arginine (Arg), histidine (His), serine (Ser), threonine (Thr), and tyrosine (Tyr); the hydrophobic amino acids are selected from at least one of alanine (Ala), valine (Val), leucine (Leu), isoleucine (Ile), phenylalanine (Phe), tryptophan (Trp), methionine (Met), and proline (Pro).
[0021] Preferably, the Pluronic series block copolymer is selected from at least one of Pluronic 124, 188, 237, 338, and 407.
[0022] Preferably, the medicinal ingredient containing acid radicals or hydroxide ions is selected from at least one of calcium hydrogen phosphate, disodium hydrogen phosphate, tricalcium phosphate, sodium bicarbonate, calcium carbonate, sodium silicate, aluminum hydroxide, calcium sulfate, and barium sulfate.
[0023] Preferably, the surface modifier 1 is selected from at least one of bile acid and its salts, PEG and its derivatives, and phospholipids.
[0024] More preferably, the surface modifier 1 is PEG and its derivatives.
[0025] More preferably, the surface modifier 1 is PEG; more preferably, the PEG is at least one selected from PEG200, PEG300, PEG400, PEG600, PEG1000, PEG1450, PEG3350, PEG4000, PEG6000, and PEG8000.
[0026] Preferably, in step (1)-step (2), the dissolution and mixing process occurs in a buffered saline solution, and the buffered saline solution is a HEPES buffer solution with a concentration of 10-30 mM and a pH of 7.0-8.5; more preferably, the concentration of the HEPES buffer solution is 20 mM and the pH is 8.0.
[0027] Preferably, in step (1), the metal salt is calcium chloride.
[0028] Preferably, in step (2), the surface modifier 2 is selected from at least one of glycocholic acid and its salts, deoxycholic acid and its salts, gentisic acid and its salts, chenodeoxycholic acid and its salts, taurocholic acid and its salts, glycocholic acid and its salts, taurodeoxycholic acid and its salts, ursodeoxycholic acid and its salts, tauroursodeoxycholic acid and its salts, phosphatidylcholine, polylysine, polylactic acid, chitosan, polyglutamic acid, and polycaprolactone.
[0029] Further preferably, the surface modifier 2 is selected from at least one of ursodeoxycholic acid, sodium chenodeoxycholate, glycocholic acid, sodium deoxycholate, gentisic acid, and sodium taurocholate.
[0030] Preferably, in step (2), the medicinal ingredient containing acid radicals or hydroxide ions is selected from at least one of disodium hydrogen phosphate, calcium hydrogen phosphate, tricalcium phosphate, sodium bicarbonate, sodium hydroxide, potassium hydroxide, magnesium hydroxide and calcium hydroxide.
[0031] Preferably, step (2) specifically comprises: dissolving and mixing the surface modifier 2 and the medicinal component containing acid radicals or hydroxide ions, and adjusting the pH to obtain liquid B.
[0032] Further preferably, in step (2), the pH is adjusted to 6.0-8.5; further preferably, the pH is adjusted to 7.0-8.5; further preferably, the pH is adjusted to 8.0.
[0033] Further preferably, after the precipitate is formed in step (3), the process further includes the steps of centrifugation and drying the precipitate to finally obtain GLP-1RA drug-loaded nanoparticles; further preferably, the centrifugation is specifically performed at 7000-10000 rpm for 8-15 min; further preferably, the centrifugation is specifically performed at 8000 rpm for 10 min.
[0034] More preferably, the drying in step (3) is freeze-drying.
[0035] More preferably, in step (3), the mixture of liquid A and liquid B needs to be shaken for 20-50 minutes during the mixing; more preferably, the mixture is shaken for 30 minutes.
[0036] Preferably, in step (3), the pH is adjusted to 6.0-8.5; further preferably, the pH is adjusted to 7.0-8.5; further preferably, the pH is adjusted to 8.0.
[0037] Furthermore, the present invention provides a GLP-1RA drug-loaded nanoparticle prepared by the above preparation method, which comprises the following components in parts by weight: 2-4 parts of GLP-1RA, 15-27 parts of HEPES, 30-48 parts of metal salt, 0.3-0.8 parts of pH regulator, 42-79 parts of surface modifier 1, 7.5-18.2 parts of surface modifier 2 and 13.5-20.7 parts of a medicinal ingredient containing acid radicals or hydroxide ions.
[0038] Preferably, the GLP-1RA drug-loaded nanoparticles comprise the following components, in parts by weight: 2.5-3.5 parts of GLP-1RA, 20-23 parts of HEPES, 36-44 parts of metal salts, 0.5-0.7 parts of pH regulators, 50-70 parts of surface modifier 1, 9-16 parts of surface modifier 2, and 15.5-18.7 parts of medicinal ingredients containing acid radicals or hydroxide ions.
[0039] Further preferably, the GLP-1RA drug-loaded nanoparticles comprise the following components, in parts by weight: 3 parts of GLP-1RA, 21.45 parts of HEPES, 39.45 parts of metal salt, 0.6 parts of pH regulator, 60 parts of surface modifier 1, 12 parts of surface modifier 2, and 17.05 parts of a medicinal ingredient containing acid radicals or hydroxide ions.
[0040] Preferably, the pH adjuster is selected from at least one of NaOH and KOH; when used, the pH adjuster is prepared with water, and the final concentration is 0.1-0.3M.
[0041] More preferably, the pH adjuster is NaOH, which is prepared into a NaOH solution with a concentration of 0.2 M when used.
[0042] Then, the present invention provides a method for preparing a GLP-1RA preparation with improved oral bioavailability, comprising the steps of: preparing a preparation by combining GLP-1RA drug-loaded nanoparticles with a penetration enhancer to obtain a GLP-1RA preparation;
[0043] The penetration enhancer is selected from at least one of medium-chain fatty acids and their derivatives, nonionic surfactants, bile acids and their derivatives, C8 (octanoic acid), C10 (decanoic acid), sodium caprate, EDTA (ethylenediaminetetraacetic acid), acylcarnitines, and alkyl maltosides.
[0044] Preferably, the medium-chain fatty acid includes but is not limited to at least one of sodium caprate, sodium laurate and ethyl laurate.
[0045] Preferably, the nonionic surfactant includes but is not limited to at least one of SNAC (sodium 8-(2-hydroxybenzamido) caprylate), 5-CNAC (sodium 5-chlorosalicylicylamide caproate), and 4-CNAB (sodium 4-chlorosalicylicylamide butyrate).
[0046] Preferably, the bile acid and its derivatives are selected from at least one of primary bile acid juice and secondary bile acid juice; further preferably, the bile acid juice is selected from at least one of bile acid, chenodeoxycholic acid, ursodeoxycholic acid, glycocholic acid, taurocholic acid, glycochenodeoxycholic acid, taurochenodeoxycholic acid, deoxycholic acid, lithocholic acid, glycodeoxycholic acid, taurodeoxycholic acid, glycolithocholic acid, taurolithocholic acid or their salts.
[0047] Preferably, the penetration enhancer is selected from at least one of SNAC, 5-CNAC, 4-CNAB, ursodeoxycholic acid, chenodeoxycholic acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid.
[0048] Preferably, the preparation of the preparation is a conventional preparation method, including but not limited to powder mixing, granulation, tableting, coating, suspension, spray drying, and hot melt extrusion steps.
[0049] Finally, the present invention provides a GLP-1RA preparation prepared by the above preparation method, which comprises the following components in parts by weight: 9-11.6 parts of GLP-1RA drug-loaded nanoparticles and 56-80 parts of a penetration enhancer.
[0050] Preferably, the GLP-1RA preparation comprises the following components, measured in parts by weight: 10.51 parts of GLP-1RA drug-loaded nanoparticles and 67.50 parts of a penetration enhancer.
[0051] Preferably, the GLP-1RA preparation further comprises a filler, a binder and a lubricant.
[0052] More preferably, the GLP-1RA preparation further comprises microcrystalline cellulose, povidone and magnesium stearate.
[0053] More preferably, the GLP-1RA preparation comprises the following components, in parts by weight: 9-11.6 parts of GLP-1RA drug-loaded nanoparticles, 56-80 parts of a penetration enhancer, 15-22 parts of a filler, 1.2-2.5 parts of a binder, and 1.8-2.6 parts of a lubricant.
[0054] More preferably, the GLP-1RA preparation comprises the following components, in parts by weight: 10.51 parts of GLP-1RA drug-loaded nanoparticles, 67.50 parts of a penetration enhancer, 18 parts of a filler, 1.8 parts of a binder, and 2.18 parts of a lubricant.
[0055] Compared with the prior art, the present invention has the following beneficial effects:
[0056] 1. The present invention uses inorganic nanoparticles as carriers, which have high drug loading, good biocompatibility and stability, can effectively protect GLP-1RA from degradation in the gastrointestinal tract, and provide multiple absorption pathways: transcellular, paracellular and M cells, thereby improving the absorption capacity of GLP-1RA in the stomach wall; and the production process is simple, which is conducive to industrial production.
[0057] 2. The present invention uses a penetration enhancer as a surface modification component, which can increase the drug loading rate of the nanoparticles and improve the drug recovery rate. It can also increase the lipophilicity of the GLP-1RA drug-loaded nanoparticles and promote their absorption through the stomach wall.
[0058] 3. The GLP-1RA drug-loaded nanoparticles prepared by the present invention have the ability to adhere to the gastric mucosa and can achieve targeting of specific parts of the digestive tract; the preparation process of the nanoparticles is simple, the materials used are all medicinal materials, the safety is high, the product composition is simple, and the stability is good.
[0059] 4. The GLP-1RA drug-loaded nanoparticles of the present invention are easily dissolved and absorbed in the gastrointestinal tract and have the characteristic of rapid drug release. This release characteristic can be modified by formulation technology methods to achieve targeted and modified release. DETAILED DESCRIPTION
[0060] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.
[0061] When the embodiments give numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints can be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention belongs.
[0062] The present invention will be further described below by way of specific embodiments.
[0063] Unless otherwise specified, the various chemical reagents used in the examples of the present invention were obtained through conventional commercial channels. In the following examples and comparative examples, the GLP-1RA used is semaglutide, purchased from Hubei Jianxiang Biopharmaceuticals, batch number COO5AD230601; polyethylene glycol 6000, purchased from Jiangxi Alpha Hi-Tech Pharmaceuticals, batch number 20230102; SNAC (sodium 8-(2-hydroxybenzamido) octanoate) was purchased from Suzhou Tianma Pharmaceutical Group Tianji Biopharmaceutical Co., Ltd., batch number 0920220901; microcrystalline cellulose was purchased from FMC, batch number 2174359392, model PH102; povidone K90 was purchased from BASF, batch number 78081424U0, model Kollidon 90 F; magnesium stearate was purchased from Anhui Shanhe Pharmaceutical Excipients Co., Ltd., batch number 230824, model SH-YM-M; ursodeoxycholic acid was purchased from Hunan Jiudian Hongyang Pharmaceutical Co., Ltd., batch number T202306LED1.
[0064] For the above components, products from different manufacturers have no significant effect on the effects.
[0065] The “ / ” in the table means that it is not used, or there is no corresponding data, or there is no corresponding content.
[0066] Example 1
[0067] A GLP-1RA drug-loaded nanoparticle, as shown in Table 1, comprises the following components in parts by weight:
[0068] Table 1
[0069]
[0070] The preparation method of GLP-1RA drug-loaded nanoparticles (semaglutide calcium phosphate particles) comprises the steps of:
[0071] (1) Solution A: Take 3.0 g of semaglutide and add it to 1500 mL of 20 mM HEPES buffer while stirring. Continue stirring until dissolved. Then add 39.42 g of calcium chloride while stirring until dissolved. Then add 30 g of PEG6000 and continue stirring until completely dissolved. Add purified water to the solution to 3000 mL and place in a cold water bath.
[0072] (2) Solution B: Weigh 30 g of PEG 6000 and add it to 600 mL of 20 mM HEPES buffer. Add 16.8 g of disodium hydrogen phosphate and stir until completely dissolved. Measure the pH and adjust the pH to 8 with sodium hydroxide. Add 20 mM HEPES buffer to 3000 mL.
[0073] (3) Slowly add solution B to solution A while stirring, and adjust the pH to 8. After the addition is completed, place the reaction solution on a shaker and continue shaking for 30 minutes to form a precipitate.
[0074] (4) Centrifugation: Centrifuge at 8000 rpm for 10 min to obtain a precipitate and a supernatant.
[0075] (5) Drying: The collected precipitate is freeze-dried to obtain the target semaglutide calcium phosphate particles.
[0076] A GLP-1RA preparation (tablet), as shown in Table 2, comprises the following components in parts by weight:
[0077] Table 2
[0078]
[0079] The unit dosage of semaglutide calcium phosphate granules is 10.51 parts based on semaglutide.
[0080] The preparation method of the GLP-1RA preparation comprises the steps of:
[0081] S1, 80% magnesium stearate, SNAC, and 70% microcrystalline cellulose were mixed evenly in a mixer;
[0082] S2, calcium phosphate nanoparticles, 30% microcrystalline cellulose, and povidone K90 were mixed uniformly in a mixer;
[0083] S3. Total mixing: The mixture obtained in step S1 and step S2 and the remaining 20% magnesium stearate are mixed evenly in a mixer, and tabletted (tabletting pressure 15-25 KN) to obtain semaglutide tablets.
[0084] The recovery amount and recovery rate of semaglutide in semaglutide calcium phosphate granules are calculated as follows:
[0085] Semaglutide recovery (g) = semaglutide loading (mg / g) × total amount of semaglutide calcium phosphate particles;
[0086] The recovery rate of semaglutide (%) = [recovered amount of semaglutide (mg) / semaglutide added amount (mg)] × 100% = 80.4%.
[0087] The prepared semaglutide tablets were subjected to dissolution behavior testing, and the test results are shown in Table 3:
[0088] RSD refers to relative standard deviation.
[0089] Table 3
[0090]
[0091] Sample NJG6248 is the marketed semaglutide tablet, produced by NOVO Nordisk and distributed by MSD Co., Ltd., with a specification of 3 mg.
[0092] Example 2
[0093] A GLP-1RA drug-loaded nanoparticle, as shown in Table 4, comprises the following components in parts by weight:
[0094] Table 4
[0095]
[0096] The preparation method of GLP-1RA drug-loaded nanoparticles (semaglutide calcium phosphate particles) comprises the steps of:
[0097] (1) Solution A: Take 3.0 g of semaglutide and add it to 1500 mL of 20 mM HEPES buffer while stirring. Continue stirring until dissolved. Then add 39.42 g of calcium chloride while stirring until dissolved. Then add 60 g of PEG6000 and continue stirring until completely dissolved. Add purified water to the solution to 3000 mL and place in a cold water bath.
[0098] (2) Solution B: Weigh 12.0 g of ursodeoxycholic acid and dissolve it in 225 mL of anhydrous ethanol. Adjust the solution to neutral with sodium hydroxide and then add it to 1200 mL of 20 mM HEPES buffer. Add 17.05 g of disodium hydrogen phosphate and stir until completely dissolved. Measure the pH and adjust the pH to 8 with sodium hydroxide. Add 20 mM HEPES buffer to 3000 mL.
[0099] (3) Slowly add solution B to solution A while stirring, and adjust the pH to 8. After the addition is completed, place the reaction solution on a shaker and continue shaking for 30 minutes to form a precipitate.
[0100] (4) Centrifugation: Centrifuge at 8000 rpm for 10 min to obtain a precipitate and a supernatant.
[0101] (5) Drying: The collected precipitate is freeze-dried to obtain the target semaglutide calcium phosphate particles.
[0102] A GLP-1RA preparation (tablet), as shown in Table 5, comprises the following components in parts by weight:
[0103] Table 5
[0104]
[0105] The unit dosage of semaglutide calcium phosphate granules is 10.51 parts based on semaglutide.
[0106] The preparation method of the GLP-1RA preparation comprises the steps of:
[0107] S1, 80% magnesium stearate, SNAC, and 70% microcrystalline cellulose were mixed evenly in a mixer;
[0108] S2, calcium phosphate nanoparticles, 30% microcrystalline cellulose, and povidone K90 were mixed uniformly in a mixer;
[0109] S3. Total mixing: The mixture obtained in step S1 and step S2 and the remaining 20% magnesium stearate are mixed evenly in a mixer, and tabletted (tabletting pressure 15-25 KN) to obtain semaglutide tablets.
[0110] The recovery amount and recovery rate of semaglutide in semaglutide tablets were calculated as follows:
[0111] Semaglutide recovery (g) = semaglutide loading (mg / g) × total amount of semaglutide calcium phosphate particles;
[0112] The recovery rate of semaglutide (%) = [recovered amount of semaglutide (mg) / semaglutide added amount (mg)] × 100% = 94.7%.
[0113] The prepared semaglutide tablets (Example 2) were tested for dissolution behavior.
[0114] The dissolution test results of semaglutide and SNAC in pH 1.2 medium are shown in Table 6.
[0115] Table 6
[0116]
[0117] Sample NJG6248 is the marketed semaglutide tablet, produced by NOVO Nordisk and distributed by MSD Co., Ltd., with a specification of 3 mg.
[0118] The dissolution test results of semaglutide and SNAC in pH 2.5 medium are shown in Table 7.
[0119] Table 7
[0120]
[0121] Sample NJG6248 is the marketed semaglutide tablet, produced by NOVO Nordisk and distributed by MSD Co., Ltd., with a specification of 3 mg.
[0122] The dissolution test results of semaglutide and SNAC in pH 6.8 medium are shown in Table 8.
[0123] Table 8
[0124]
[0125] Sample NJG6248 is the marketed semaglutide tablet, produced by NOVO Nordisk and distributed by MSD Co., Ltd., with a specification of 3 mg.
[0126] It can be seen from the dissolution results in Tables 2 to 4 that the dissolution of API and SNAC in the semaglutide preparation of the present invention in each dissolution medium is faster than that of the control preparation NJG6248, and the dissolution amount is higher.
[0127] Example 3
[0128] Different from Example 2, the preparation of the GLP-1RA preparation is different, including the steps of:
[0129] S1. Pretreatment: Sodium 8-(2-hydroxybenzamido)octanoate was granulated. SNAC was granulated using a 0.61 mm sieve at 1300 rpm.
[0130] S2. Weighing: Weigh each ingredient according to the formula amount.
[0131] S3, Mixed:
[0132] The sample of step S1 was mixed: 80% of the sieved magnesium stearate was mixed with 2% SNAC, mixed at 20 rpm for 2 min, 4% SNAC was added and continued to mix, mixed at 20 rpm for 2 min, and then the remaining SNAC was added and mixed at 20 rpm for 20 min; 30% microcrystalline cellulose was added to the mixer, mixed at 20 rpm for 10 min, and a mixture S1 was obtained;
[0133] The samples of step S2 were mixed: first, an amount of microcrystalline cellulose equal to the amount of semaglutide drug-loaded particles in the formula was mixed at 20 rpm for 2 min; finally, the remaining microcrystalline cellulose and povidone were added and mixed at 20 rpm for 10 min to obtain a mixture S2.
[0134] S4, dry granulation:
[0135] Granulation of mixture S1: feed screw speed 35.0 rpm, roller speed 6.0 rpm, pressure 100 bar, roller gap 0.60 mm, to obtain S1 granules;
[0136] The mixture S2 was granulated: the feed screw speed was 30.0 rpm, the roller speed was 4.0 rpm, the pressure was 110 bar, and the roller gap was 0.60 mm; S2 granules were obtained.
[0137] S5, whole grain:
[0138] The S1 particles were sieved using a 0.61 mm sieve at 1300 rpm, and the resulting particles were collected and weighed to calculate the yield.
[0139] The S2 particles were sieved using a 0.61 mm sieve at 1300 rpm, and the resulting particles were collected and weighed to calculate the yield.
[0140] S6. Weighing:
[0141] Based on the weight and yield of S1 granules and S2 granules, the actual amount of additional magnesium stearate to be added is calculated; and the target amount of magnesium stearate is obtained by weighing.
[0142] S7, total mixing:
[0143] The S1 granules and the S2 granules were mixed in a mixer at 20 rpm for 25 min, and then magnesium stearate was added and mixed at 20 rpm for 3 min to obtain an intermediate product powder.
[0144] S8, Tableting:
[0145] The intermediate product powder is pressed into tablets (semaglutide tablets) with a specification of 14 mg and a hardness of 50-100N using a rotary tablet press.
[0146] The prepared semaglutide tablets (Example 3) were tested for dissolution behavior.
[0147] The dissolution test results of semaglutide and SNAC in pH 1.2 medium are shown in Table 9.
[0148] Table 9
[0149]
[0150] The NJG6248 sample is a marketed semaglutide tablet produced by NOVO Nordisk and distributed by MSD Co., Ltd., with a specification of 3 mg.
[0151] Example 4
[0152] The difference from Example 2 is that ursodeoxycholic acid is replaced by sodium chenodeoxycholate. The rest is the same as Example 1.
[0153] The prepared GLP-1RA preparation was tested for dissolution behavior. The test results are shown in Table 10.
[0154] Table 10
[0155]
[0156] Example 5
[0157] The difference from Example 2 is that ursodeoxycholic acid is replaced by sodium taurocholate. The rest is the same as Example 1.
[0158] The prepared GLP-1RA preparation was tested for dissolution behavior, and the test results are shown in Table 11.
[0159] Table 11
[0160]
[0161] Comparative Example 1
[0162] Different from Example 2, the type of surface modifier 2 is different, and the specific type is shown in Table 12. The test results of the recovery rate of semaglutide in the prepared GLP-1RA preparation (semaglutide tablets) are shown in Table 12.
[0163] Table 12
[0164]
[0165] Semaglutide recovery (g) = semaglutide loading (mg / g) × total amount of semaglutide calcium phosphate particles;
[0166] Recovery rate of semaglutide (%) = [recovered amount of semaglutide (mg) / added amount of semaglutide (mg)] × 100%.
[0167] Comparative Example 2
[0168] The difference from Example 2 is that the weight proportions of the components in the GLP-1RA drug-loaded nanoparticles are different. Specifically, as shown in Table 13:
[0169] Table 13
[0170]
[0171] The prepared GLP-1RA preparation was tested for dissolution behavior. The test results are shown in Table 14.
[0172] The recovery rate of semaglutide was 65%.
[0173] Table 14
[0174]
[0175] Comparative Example 3
[0176] The difference from Example 2 is that the penetration enhancer is different, and SNAC is replaced by sodium lauroyl alanine.
[0177] The prepared GLP-1RA preparation was tested for dissolution behavior. The test results are shown in Table 15.
[0178] The recovery rate of semaglutide was 62%.
[0179] Table 15
[0180]
[0181] Comparative Example 4
[0182] Different from Example 2, the preparation method of GLP-1RA drug-loaded nanoparticles is different, as shown in Table 16:
[0183] Add semaglutide, PEG6000 and ursodeoxycholic acid ethanol solution into 20 mM HEPES buffer, add disodium hydrogen phosphate, stir until completely dissolved, measure the pH, and adjust the pH to 8 with sodium hydroxide; then add to calcium chloride solution while stirring, shake to precipitate, centrifuge, and dry to obtain.
[0184] The prepared GLP-1RA preparation was tested for dissolution behavior. The test results are shown in Table 16.
[0185] The recovery rate of semaglutide was 47%.
[0186] Table 16
[0187]
[0188] Comparative Example 5
[0189] Different from Example 2, the weight parts of the components in the GLP-1RA preparation are different, as shown in Table 17:
[0190] Table 17
[0191]
[0192] The prepared GLP-1RA preparation was tested for dissolution behavior. The test results are shown in Table 18.
[0193] The recovery rate of semaglutide was 70%.
[0194] Table 18
[0195]
[0196] Bioavailability and safety testing
[0197] (1) Research objectives
[0198] The semaglutide tablets (trade name: Rybelsus) licensed by NOVO NORDISK INC were used as the control preparation;
[0199] The semaglutide tablets prepared in Example 2 were used as the test preparation, and the relative bioavailability of the two preparations in humans was evaluated through a single-center, randomized, open, single-dose, parallel-design clinical study.
[0200] At the same time, the safety of the test preparation and the control preparation in healthy Chinese subjects was observed.
[0201] (2) Study drugs
[0202] Test preparation (T): semaglutide tablets of Example 2, specification: 14 mg.
[0203] Control preparation (R): Semaglutide tablets (trade name: Rybelsus), strength: 14 mg, licensed by NOVO NORDISK INC.
[0204] (3) Experimental design
[0205] A single-center, random, open, single-dose, and parallel trial design was adopted. Subjects were divided into T and R groups according to random principles, and received the subject preparation or control preparation on an empty stomach. 6 healthy subjects in the word fasting test were given, and the dosage was 14 mg. Experimental blood collection time points: 0 h before dosage (within 60 min) and 15 min, 30 min, 45 min, 1 h, 75 min, 1.5 h, 105 min, 2 h, 2.5 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 24 h, 48 h, 72 h after dosage, venous blood was collected at a total of 20 time points.
[0206] (4) Dosage method
[0207] The subjects fasted overnight for at least 10 hours in the first cycle, and took the test preparation or control preparation with 120 mL of warm water on an empty stomach the next morning. When administering the medicine, the researchers instructed the subjects not to chew the medicine, but to swallow the whole tablet or pill. After taking the medicine, the mouth, medicine container, water cup and hands should be checked to ensure that the medicine and water have been taken.
[0208] The subjects were prohibited from drinking water from 1 hour before to 1 hour after taking the medicine (except 120 mL of water given at the time of administration), and were prohibited from eating within 5 hours after taking the medicine.
[0209] (5) Blood collection
[0210] Blood samples were collected at 0h before administration and 15min, 30min, 45min, 1h, 75min, 1.5h, 105min, 2h, 2.5h, 3h, 4h, 5h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after administration.
[0211] Sample collection was carried out according to the sampling protocol and the SOP of the clinical hospital. Each blood sample was collected at the specified theoretical time point, and the actual collection time of each blood sample was recorded in full. See the blood collection schedule for details. Prepare sufficient anticoagulant blood vessels with sodium heparin before collecting blood samples. The researchers will uniformly number them according to the protocol and label them with sample, and at the same time, the frozen storage tubes are uniformly numbered and special labels are pasted. Take about 4mL of blood in the vein and mix gently up and down 5-6 times. Before alising the whole blood sample, gently reverse the blood collection tube to evenly distribute the blood cells, immediately remove 1 mL of whole blood into the detection tube and transfer the remaining whole blood to the backup tube. All-in-one ice bath.
[0212] All blood samples of the subjects were placed in an ultra-low temperature refrigerator within 2 hours after collection.
[0213] All blood samples were tested after the two-cycle test was completed.
[0214] (6) Calculation of pharmacokinetic parameters
[0215] The pharmacokinetic parameters were calculated using nonparametric statistical modeling.
[0216] (7) Test results
[0217] The pharmacokinetic parameters of semaglutide are shown in Table 19.
[0218] Table 19
[0219]
[0220] Therefore, the GLP-1RA preparation prepared by the present invention exhibits a bioavailability exceeding that of commercially available preparations in human pharmacokinetic studies, indicating that the formulation process of the present invention significantly improves the oral absorption of semaglutide.
[0221] In summary, the preparation method of the present invention and the prepared GLP-1RA preparation have the following technical effects:
[0222] 1. The dissolution rate and dissolution amount of GLP-1RA are improved. Since the obtained inorganic nanoparticles have a small particle size and a rapid reaction, the dissolution rate and drug dissolution amount are higher than those of ordinary oral GLP-1RA preparations.
[0223] 2. The drug loading capacity and drug recovery rate (over 85%) are improved. By using penetration enhancers as surface modifiers, the drug recovery rate is improved and the loss in the preparation process is reduced.
[0224] 3. The inorganic nanocarrier of mucosal adhesion and technical solutions for penetration promotion are combined to promote the absorption of drugs in the gastrointestinal tract; the inorganic nanoparticles adhered to mucosa can target the gastric or intestinal mucosa, effectively protect oral polypeptide drugs from degradation of the gastrointestinal tract, and at the same time provide a variety of absorption pathways to improve their gastric wall absorption capacity; the penetration promoter can change the physical and biochemical properties of the intestinal wall barrier, increase the intestinal wall permeability of oral polypeptide drugs, improve the absorption capacity, increase the solubility of the drug, and improve its bioavailability.
[0225] 4. The preparation method of the present invention can achieve effective delivery of oral polypeptide drugs, overcome the inconvenience and pain of traditional injection administration, and improve patient compliance and quality of life.
[0226] 5. The preparation method of the present invention can protect oral polypeptide drugs from degradation in the gastrointestinal tract and the first-pass effect of the liver, thereby improving the bioavailability and efficacy of oral polypeptide drugs and reducing the dosage and toxic side effects of the drugs.
[0227] 6. The preparation method of the present invention can achieve controlled release and targeted therapy of oral polypeptide drugs, improve the pharmacokinetic and pharmacodynamic properties of oral polypeptide drugs, and enhance the therapeutic effect and safety of oral polypeptide drugs.
[0228] 7. The preparation method of the present invention adopts a simple, economical and feasible preparation method and raw materials, which improves the convenience and economy of manufacturing and storage of oral polypeptide drugs and has a strong prospect for industrial application.
[0229] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A method for preparing a GLP-1RA preparation with improved oral bioavailability, It is characterized in that The method comprises the following steps: preparing a preparation of GLP-1RA drug-loaded nanoparticles together with a penetration enhancer, 8-(2-hydroxybenzamide) sodium caprylate, to obtain a GLP-1RA preparation; the GLP-1RA preparation further comprises a filler, a binder and a lubricant; the GLP-1RA preparation comprises the following components, measured by weight: 9-11.6 parts of GLP-1RA drug-loaded nanoparticles, 56-80 parts of 8-(2-hydroxybenzamide) sodium caprylate, 15-22 parts of a filler, 1.2-2.5 parts of a binder and 1.8-2.6 parts of a lubricant; the filler is microcrystalline cellulose, the binder is povidone, and the lubricant is magnesium stearate; The method for preparing the GLP-1RA drug-loaded nanoparticles comprises the steps of: (1) GLP-1RA, surface modifier 1 polyethylene glycol 6000 and calcium chloride are dissolved and mixed to obtain liquid A; (2) surface modifier 2 and a medicinal component containing acid radicals or hydroxide ions are dissolved and mixed to obtain liquid B; the surface modifier 2 is selected from at least one of ursodeoxycholic acid, sodium chenodeoxycholate, sodium taurocholate, sodium deoxycholate, gentisic acid and glycocholic acid; the medicinal component containing acid radicals or hydroxide ions is disodium hydrogen phosphate; (3) Liquid A and liquid B are mixed, the pH is adjusted, a precipitate is formed, and GLP-1RA drug-loaded nanoparticles are obtained; In the preparation method of GLP-1RA drug-loaded nanoparticles, the weight ratio of each component is: 2-4 parts of GLP-1RA, 15-27 parts of HEPES, 30-48 parts of calcium chloride, 0.3-0.8 parts of pH regulator, 42-79 parts of surface modifier 1, 7.5-18.2 parts of surface modifier 2 and 13.5-20.7 parts of medicinal ingredients containing acid radicals or hydroxide ions; the GLP-1RA is semaglutide; the dissolution and mixing process occurs in a buffered saline solution, the buffered saline solution is a HEPES buffer solution with a concentration of 10-30mM and a pH of 7.0-8.
5.
2. The preparation method according to claim 1, It is characterized in that In step (3), the pH is adjusted to 6.0-8.
5. After the precipitate is formed in step (3), the method further comprises the steps of centrifugation and drying the precipitate, and finally obtaining GLP-1RA drug-loaded nanoparticles.
3. The GLP-1RA preparation prepared by the preparation method according to any one of claims 1 to 2.
